Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SRRK

Scholar Rock Holding Corp

Oct 22 • 04:00PM ET

28.52

+0.35 1.24 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN NBIX SRPT BMRN RARE FOLD IONS BLUE TVRD

| Held by: VTI XBI IWM VXF IWO VTWO IBB SCHA VHT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.02	Insider Own	23.10%	Shs Outstand	96.00M	Perf Week	-11.98%
Market Cap	2.74B	Forward P/E	-	EPS next Y	-2.71	Insider Trans	1.67%	Shs Float	73.92M	Perf Month	-15.50%
Enterprise Value	2.51B	PEG	-	EPS next Q	-0.84	Inst Own	99.19%	Short Float	22.21%	Perf Quarter	-27.08%
Income	-315.69M	P/S	-	EPS this Y	-33.77%	Inst Trans	3.09%	Short Ratio	6.67	Perf Half Y	-12.30%
Sales	0.00M	P/B	11.74	EPS next Y	17.84%	ROA	-111.37%	Short Interest	16.42M	Perf YTD	-34.01%
Book/sh	2.43	P/C	9.29	EPS next 5Y	11.97%	ROE	-172.08%	52W High	46.98 -39.29%	Perf Year	-6.64%
Cash/sh	3.07	P/FCF	-	EPS past 3/5Y	11.76% -5.90%	ROIC	-109.00%	52W Low	22.71 25.58%	Perf 3Y	296.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.99% 7.80%	Perf 5Y	104.01%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-29.50%	Oper. Margin	-	ATR (14)	2.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	36.71	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	6.33	EPS Q/Q	-61.56%	SMA20	-17.95%	Beta	0.84	Target Price	46.91
Payout	-	Debt/Eq	0.26	Sales Q/Q	-	SMA50	-14.87%	Rel Volume	1.24	Prev Close	28.17
Employees	196	LT Debt/Eq	0.24	Earnings	Aug 06 BMO	SMA200	-17.93%	Avg Volume	2.46M	Price	28.52
IPO	May 24, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-47.41% -	Trades		Volume	3,038,908	Change	1.24%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-25	Initiated	BofA Securities	Buy	$53
Sep-17-25	Initiated	Barclays	Overweight	$45
Sep-15-25	Initiated	Leerink Partners	Outperform	$51
Aug-21-25	Resumed	Jefferies	Buy	$50
Jul-30-25	Resumed	Raymond James	Strong Buy	$53
Jul-17-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Reiterated	H.C. Wainwright	Buy	$40 → $50
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65
Jan-06-21	Initiated	JP Morgan	Overweight	$59
Mar-12-20	Initiated	Robert W. Baird	Outperform	$35

Show Previous Ratings

Oct-17-25 06:15PM	Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Oct-13-25 05:22PM	Why Scholar Rock Stock Got Socked on Monday (Motley Fool) -13.14% -6.93%
Oct-09-25 05:07PM	Why Scholar Rock Stock Raced 6% Higher Today (Motley Fool) +5.94%
01:10PM	Loading…
Oct-08-25 01:10PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-23-25 04:06PM	Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback (Investor's Business Daily)
10:04AM	Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
07:00AM	FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility (Business Wire)
06:19AM	Scholar Rock SMA drug rejected by FDA over manufacturing concerns (BioPharma Dive)
Sep-15-25 04:54PM	Why Scholar Rock Stock Bounced Higher on Monday (Motley Fool) +6.32%
Sep-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 03:31AM	Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger? (Insider Monkey)
Aug-21-25 12:18PM	Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD (Insider Monkey)
04:15PM	Loading…
Aug-15-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:20AM	Veru Announces Novel Modified-Release Oral Formulation for Enobosarm (Zacks)
Aug-14-25 08:00AM	Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment (Business Wire)
Aug-11-25 08:21PM	Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss (Insider Monkey)
Aug-06-25 05:10PM	Why Scholar Rock Stock Wilted on Wednesday (Motley Fool) -6.40% -9.30%
07:00AM	Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
Jul-21-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 (Business Wire)
Jul-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-23-25 08:00AM	Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial (Business Wire)
Jun-20-25 03:45PM	Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says (Reuters) -6.28%
Jun-19-25 02:01PM	Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial (Insider Monkey)
Jun-18-25 01:41PM	Why Scholar Rock Shares Are Soaring Today (Motley Fool) +16.60%
11:40AM	Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results (Investopedia)
07:42AM	Scholar Rock drug preserves muscle in obesity trial (BioPharma Dive)
07:00AM	Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss (Business Wire)
04:15PM	Loading…
Jun-13-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 08:00AM	Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire) +11.13%
Jun-02-25 08:00AM	Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager (Business Wire)
May-28-25 08:00AM	Scholar Rock to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.28%
May-16-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-25 03:10AM	Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ... (GuruFocus.com)
01:39AM	Q1 2025 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:00AM	Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
May-13-25 09:24AM	What To Expect From Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings (GuruFocus.com)
May-07-25 08:00AM	Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 (Business Wire)
May-06-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.01%
Apr-28-25 07:08PM	Why Scholar Rock Stock Took a Knock on Monday (Motley Fool)
06:50AM	Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth (Business Wire)
Apr-23-25 06:34PM	Why Scholar Rock Holding Stock Topped the Market Today (Motley Fool) +5.72%
Apr-21-25 04:37PM	Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ... (GuruFocus.com) +6.14%
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-25-25 07:30AM	FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy (Business Wire)
Mar-17-25 08:31AM	Scholar Rock SMA drug shows muscle function benefit (Clinical Trials Arena)
Mar-16-25 07:00PM	Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
Mar-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 11:16PM	Q4 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents) +7.95%
07:00AM	Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress (Business Wire)
Feb-26-25 07:24AM	Earnings To Watch: Scholar Rock Holding Corp (SRRK) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 04:15PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-25 01:10PM	Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now? (Insider Monkey)
Feb-21-25 08:00AM	Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Feb-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-10-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025 (Business Wire)
Jan-29-25 08:05AM	Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
08:00AM	Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition (Business Wire)
Jan-17-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-13-25 06:48PM	Heres Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing (Insider Monkey) +5.21%
Jan-08-25 04:00PM	Scholar Rock Highlights 2025 Strategic Priorities (Business Wire)
Jan-02-25 08:00AM	Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-04-24 12:36PM	Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga) +26.07%
06:13AM	Biohaven muscle drug misses goal of SMA study, but advances in obesity (BioPharma Dive)
Nov-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 02:08AM	Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 07:00AM	Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress (Business Wire) -5.29%
Nov-11-24 07:07AM	Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin (Business Wire)
Nov-01-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (Business Wire)
Oct-31-24 04:00PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire) -5.14%
08:00AM	Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting (Business Wire)
Oct-22-24 08:00AM	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Business Wire)
Oct-21-24 09:55AM	Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? (Zacks)
Oct-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-11-24 06:30PM	PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors (Barrons.com) +7.58%
Oct-09-24 05:34PM	Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ... (GuruFocus.com) -5.83% -5.87%
05:38AM	Here's Why Everybody's Talking About Scholar Rock Right Now (Motley Fool)
Oct-08-24 11:08PM	Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -13.97%
08:29AM	Scholar Rocks SMA Treatment Trials Show Promising Results (TipRanks)
06:43AM	Scholar Rock stocks skyrocket after SMA drug scores at Phase III (Clinical Trials Arena)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +361.99%
04:09PM	Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
03:23PM	Scholar Rock Shares Quadruple On Positive Drug-Study Results (The Wall Street Journal)
11:05AM	Scholar Rock stock surges on positive spinal muscular atrophy treatment data (Investing.com)
11:05AM	Scholar Rock Stock Quadruples on Positive Trial Data (Barrons.com)
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
07:00AM	Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
Sep-27-24 06:13AM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now (Insider Monkey)
Sep-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.48%
Sep-10-24 08:00AM	Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity (Business Wire) +5.89%
Sep-05-24 12:02AM	Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	Oct 03 '25	Buy	37.27	387,414	14,438,544	387,414	Oct 07 08:59 PM
AKKARAJU SRINIVAS	Director	Oct 06 '25	Buy	38.65	113,025	4,368,808	500,439	Oct 07 08:59 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 22 '25	Sale	30.67	3,353	102,846	108,964	Sep 24 04:30 PM
Mohammed Qatanani	Officer	Sep 22 '25	Proposed Sale	30.67	3,353	102,846		Sep 22 04:33 PM
Peng Katie	Director	Sep 16 '25	Sale	32.53	1,006	32,726	33,914	Sep 17 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '25	Sale	33.52	3,178	106,527	112,317	Sep 17 04:30 PM
Katie Peng	Director	Sep 16 '25	Proposed Sale	32.53	1,006	32,726		Sep 16 04:32 PM
Parlavecchio Caryn	CHRO	Aug 18 '25	Sale	31.17	2,178	67,880	155,464	Aug 19 04:30 PM
FLIER JEFFREY S.	Director	Jul 16 '25	Sale	40.02	11,136	445,688	0	Jul 18 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jul 08 '25	Sale	34.44	24,066	828,898	115,495	Jul 10 09:46 PM
Mohammed Qatanani	Officer	Jul 08 '25	Proposed Sale	35.48	24,066	853,862		Jul 08 04:12 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Option Exercise	21.62	20,316	439,232	44,386	Jun 25 04:30 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Sale	32.24	20,316	654,904	24,070	Jun 25 04:30 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Sale	33.21	11,136	369,818	11,136	Jun 25 04:30 PM
Peng Katie	Director	Jun 16 '25	Sale	31.97	3,031	96,888	34,920	Jun 17 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 16 '25	Sale	32.00	3,668	117,381	139,561	Jun 17 04:30 PM
Parlavecchio Caryn	CHRO	Jun 16 '25	Sale	32.00	6,186	197,961	157,642	Jun 17 04:30 PM
Ho Junlin	GENERAL COUNSEL	Jun 16 '25	Sale	32.00	7,442	238,154	222,569	Jun 17 04:30 PM
Edward Myles	Former Officer	Jun 05 '25	Proposed Sale	32.50	19,599	636,967		Jun 05 04:57 PM
FLIER JEFFREY S.	Director	May 29 '25	Sale	29.73	6,075	180,584	24,070	May 30 04:32 PM
Burow Kristina	Director	May 29 '25	Sale	29.72	5,400	160,511	21,071	May 30 04:31 PM
Gilman Michael	Director	May 29 '25	Sale	29.72	3,375	100,304	55,216	May 30 04:31 PM
Brudnick Richard	Director	May 29 '25	Sale	29.72	6,075	180,531	15,057	May 30 04:31 PM
Reed Joshua	Director	May 29 '25	Sale	29.72	5,400	160,463	15,732	May 30 04:30 PM
Vaishnaw Akshay	President of R&D	May 29 '25	Sale	29.72	6,750	200,612	616,205	May 30 04:30 PM
Akshay Vaishnaw	Director	May 29 '25	Proposed Sale	29.66	6,750	200,205		May 29 04:51 PM
Joshua Reed	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:49 PM
Michael Gilman	Director	May 29 '25	Proposed Sale	29.66	3,375	100,103		May 29 04:46 PM
Jeffrey S. Flier	Director	May 29 '25	Proposed Sale	29.66	48,663	1,443,345		May 29 04:43 PM
Kristina Burow	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:39 PM
Richard Brudnick	Director	May 29 '25	Proposed Sale	29.66	6,075	180,185		May 29 04:35 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Option Exercise	10.00	5,000	50,000	76,250	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Sale	32.83	5,000	164,131	71,750	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Option Exercise	10.00	5,000	50,000	78,250	Mar 25 07:39 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Sale	33.08	6,500	215,014	71,750	Mar 25 07:39 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Option Exercise	17.33	13,564	235,085	96,173	Mar 25 07:37 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Sale	33.12	13,564	449,237	82,609	Mar 25 07:37 PM
Tracey Sacco	Affiliate	Mar 24 '25	Proposed Sale	33.00	41,500	1,369,500		Mar 24 07:20 PM
Peng Katie	Director	Mar 17 '25	Sale	34.42	1,006	34,627	30,319	Mar 19 05:00 PM
Katie Peng	Director	Mar 17 '25	Proposed Sale	34.60	4,037	139,680		Mar 17 06:50 PM
Myles Edward H	COO & CFO	Mar 10 '25	Option Exercise	13.60	112,897	1,535,083	253,637	Mar 12 07:06 PM
Myles Edward H	COO & CFO	Mar 10 '25	Sale	35.62	142,292	5,068,974	111,345	Mar 12 07:06 PM
Edward Myles	Officer	Mar 10 '25	Proposed Sale	35.00	161,890	5,666,150		Mar 10 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Option Exercise	10.19	48,308	492,186	179,594	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Sale	37.40	68,510	2,562,479	111,084	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	36.83	4,135	152,288	131,286	Feb 20 07:55 PM
Parlavecchio Caryn	CHRO	Feb 18 '25	Sale	36.83	5,296	195,046	140,258	Feb 20 06:30 PM
Myles Edward H	COO & CFO	Feb 18 '25	Sale	36.83	7,809	287,598	140,740	Feb 20 06:18 PM
Ho Junlin	GENERAL COUNSEL	Feb 18 '25	Sale	36.83	5,742	211,472	189,295	Feb 20 05:53 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	36.83	18,372	676,622	311,991	Feb 20 05:41 PM
Mohammed Qatanani	Officer	Feb 19 '25	Proposed Sale	36.95	68,510	2,531,444		Feb 19 04:15 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Jan 16 '25	Sale	44.20	22,308	985,951	330,363	Jan 21 04:35 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Jan 16 '25	Sale	44.20	5,655	249,935	67,200	Jan 21 04:35 PM
Sacco Tracey	Chief Commercial Officer	Jan 16 '25	Sale	44.20	3,890	171,927	45,395	Jan 21 04:35 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 16 '25	Sale	44.20	7,347	324,717	135,421	Jan 21 04:35 PM
Parlavecchio Caryn	CHRO	Jan 16 '25	Sale	44.20	6,434	284,365	145,554	Jan 21 04:35 PM
Myles Edward H	COO & CFO	Jan 16 '25	Sale	44.20	12,539	554,189	148,549	Jan 21 04:35 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '25	Sale	44.20	9,039	399,498	195,037	Jan 21 04:35 PM
Invus Public Equities, L.P.	10% Owner	Dec 10 '24	Sale	41.65	1,600,000	66,640,000	9,250,005	Dec 12 04:39 PM
Invus Public Equities, L.P.	10% Owner	Nov 25 '24	Sale	38.49	409,433	15,757,639	10,850,005	Nov 27 04:31 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Option Exercise	8.59	6,375	54,761	79,230	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Option Exercise	8.59	2,145	18,426	75,000	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Sale	39.44	6,375	251,399	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Sale	30.01	2,145	64,372	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Option Exercise	8.59	2,105	18,082	74,960	Nov 13 04:40 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Sale	30.00	2,105	63,158	72,855	Nov 13 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRRK

Scholar Rock Holding Corp

Upgrade your FINVIZ experience